TGTX - TG Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5640.39M
Enterprise Value 3527.96M
Trailing P/E N/A
Forward P/E 1-5.47
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)4,213.08
Price/Book (mrq)30.39
Enterprise Value/Revenue 33,473.41
Enterprise Value/EBITDA 6-3.15

Trading Information

Stock Price History

Beta (3Y Monthly) 1.88
52-Week Change 3-48.45%
S&P500 52-Week Change 37.14%
52 Week High 314.10
52 Week Low 33.32
50-Day Moving Average 37.14
200-Day Moving Average 36.22

Share Statistics

Avg Vol (3 month) 31.73M
Avg Vol (10 day) 31.59M
Shares Outstanding 590.84M
Float 55.7M
% Held by Insiders 111.16%
% Held by Institutions 168.87%
Shares Short (Jun 14, 2019) 414.43M
Short Ratio (Jun 14, 2019) 410.01
Short % of Float (Jun 14, 2019) 422.18%
Short % of Shares Outstanding (Jun 14, 2019) 415.88%
Shares Short (prior month May 15, 2019) 415.26M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 256/1
Last Split Date 3Apr 30, 2012

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-110,205.26%

Management Effectiveness

Return on Assets (ttm)-87.78%
Return on Equity (ttm)-319.87%

Income Statement

Revenue (ttm)152k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)0.00%
Gross Profit (ttm)152k
EBITDA -167.42M
Net Income Avi to Common (ttm)-167.11M
Diluted EPS (ttm)-2.14
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)92.47M
Total Cash Per Share (mrq)1.08
Total Debt (mrq)37.86M
Total Debt/Equity (mrq)196.65
Current Ratio (mrq)1.72
Book Value Per Share (mrq)0.23

Cash Flow Statement

Operating Cash Flow (ttm)-134.23M
Levered Free Cash Flow (ttm)-71.45M